Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)

Inclusion criteria

• . Patients whose age at the time of consent acquisition is between 20 and 80 years old.
• . Patients who have been diagnosed with pulmonary arterial hypertension (PAH) and fall into one of the following among the first group of the clinical classification of pulmonary hypertension (Nice Classification, 2018) Idiopathic pulmonary arterial hypertension (IPAH) Hereditary pulmonary arterial hypertension (HPAH) Drug/toxin-induced pulmonary arterial hypertension Pulmonary arterial hypertension associated with connective tissue disease Pulmonary arterial hypertension associated with congenital heart disease (only after repair surgery)
• . Patients in the World Health Organization (WHO) Functional Classification (FC) I, II, or III.
• . Patients with immune responsive-phenotype
• . Patients with a 6-minute walking distance of 150 to 600 meters at screening.
• . Patients whose resting hemodynamic values within 30 days prior to enrollment meet all of the following Mean pulmonary artery pressure (mPAP) is 25 mmHg or higher PVR is higher than 4 Wood units
• . Patients who are using up to three PAH drugs and have not changed the dosage and administration for at least 90 days prior to enrollment
• . Patients who are receiving home oxygen therapy under the same conditions for at least 30 days prior to enrollment

Exclusion criteria